Spinal Muscular Atrophy Treatment Market Analysis

Treatment Type Segment Analysis

The medication segment is expected to register a considerable share in the spinal muscular atrophy treatment market. The segment is driven by the widespread use of RNA-based drugs such as Biogen’s Spinraza. Additionally, newer medicines including Evrysdi have provided more convenient and accessible options for patients, further bolstering the medication segment. These drugs are favored as they offer ongoing treatment options compared to one-time, high-cost gene therapies. Moreover, both oral and injectable formulations’ availability, improved accessibility to treatment, permitting different preferences and needs to be met with effective therapy. The continuous need for dosage over time provides a steady demand, making medications a key revenue-generating segment in the market.

Route of Administration Segment Analysis

Oral segment is likely to dominate spinal muscular atrophy treatment market share of over 62.9% by 2035. Administration of oral SMA treatments at home does not require clinical visits, reducing the load on patients and their families. It is particularly convenient for long-term treatment regimens, as visits to hospitals can be disruptive. This thereby drives the market growth significantly. Furthermore, oral therapies eliminate the need for healthcare resources including nursing support for injections or infusion centers. Cost savings due to this make oral treatments a more appealing option for payers and providers, hence, accelerating their adoption and boosting market growth.

Our in-depth analysis of the market includes the following segments: